Physician profile
Jennifer Lynn Geremia
NPI 1154443976
$370,023.61
in general payments reported to CMS, 2019-2025
19 companies · $142K in 2025
The $142K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17K · 2022: $43K · 2023: $60K · 2024: $108K · 2025: $142K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200K · Travel and Lodging: $74K · Consulting Fee: $22K · Food and Beverage: $14K · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200,164.86 |
| Travel and Lodging | $74,120.69 |
| Consulting Fee | $21,744.50 |
| Food and Beverage | $14,150.55 |
| Education | $161.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $113,396.18 | 2021-2025 | |
| Madrigal Pharmaceuticals | $88,997.33 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $50,234.98 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $30,684.54 | 2024-2025 | Voquezna |
| Pfizer INC. | $24,641.72 | 2021-2025 | |
| Lilly USA, LLC | $24,383.15 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $16,174.08 | 2025 | Iqirvo, Bylvay |
| Aimmune Therapeutics, INC. | $6,007.31 | 2024-2025 | Zenpep |
| Celgene Corporation | $4,782.01 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,641.42 | 2022-2023 | Xifaxan, Trulance, Relistor |
| Nestle Healthcare Nutrition INC. | $2,588.82 | 2021-2022 | |
| Genentech USA, INC. | $2,395.76 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,677.76 | 2022-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $500.00 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $250.00 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $229.49 | 2024-2025 | |
| Novo Nordisk INC | $170.97 | 2024-2025 | Wegovy |
| Boston Scientific Corporation | $142.72 | 2022 | |
| Janssen Biotech, INC. | $125.37 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Geremia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.